Galderma Launches Sculptra in China
The launch follows regulatory approval and study results supporting Sculptra’s long-lasting correction of midface volume and contour loss.
The launch follows regulatory approval and study results supporting Sculptra’s long-lasting correction of midface volume and contour loss.
Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.